This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ali, S. M. Articles by Lipton, A. Search for Related Content PubMed PubMed Citation Articles by Ali, S. M. Articles by Lipton, A. Social Bookmarking                            What's this?

Safety and Efficacy of Bisphosphonates Beyond 24 Months in Cancer Patients

From the M.S. Hershey Medical Center, Hershey, PA.

Address reprint requests to Allan Lipton, MD, Division of Hematology/Medical Oncology, 500 University Dr, PO Box 850, HO46, Hershey, PA 17033; email: alipton{at}psu.edu

PURPOSE: Bisphosphonate therapy has decreased the risk of skeletal complications associated with osteolytic bone lesions in patients with breast cancer and multiple myeloma. The large prospective studies have used 21 to 24 months of treatment. We studied the safety and efficacy of bisphosphonates in a subset of patients who received therapy for more than 24 months.

PATIENTS AND METHODS: Patients who received bisphosphonates (pamidronate or zoledronic acid) were identified. Data on skeletal events and laboratory parameters were gathered by chart review.

RESULTS: We studied 22 patients who received intravenous pamidronate or zoledronic acid for a duration of 3.6 years (range, 2.2 to 6.0 years). Prolonged therapy was well tolerated. No significant calcium, phosphorus, electrolyte, or WBC count abnormalities were encountered. There was a clinically insignificant decrease in hemoglobin and platelet count and an increase in creatinine in these patients. The fracture rate beyond 2 years was no greater than during the first 2 years of treatment. There were no stress fractures of long bones with prolonged therapy.

CONCLUSION: Prolonged treatment with the potent bisphosphonates pamidronate and zoledronic acid seems to be well tolerated and should be studied in prospective, randomized studies to document prolonged skeletal efficacy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Labrinidis, S. Hay, V. Liapis, V. Ponomarev, D. M. Findlay, and A. Evdokiou Zoledronic Acid Inhibits Both the Osteolytic and Osteoblastic Components of Osteosarcoma Lesions in a Mouse Model Clin. Cancer Res., May 15, 2009; 15(10): 3451 - 3461. [Abstract] [Full Text] [PDF]

				S. H. Giordano, S. Fang, Z. Duan, Y.-F. Kuo, G. N. Hortobagyi, and J. S. Goodwin Use of Intravenous Bisphosphonates in Older Women with Breast Cancer Oncologist, May 1, 2008; 13(5): 494 - 502. [Abstract] [Full Text] [PDF]

				D.B. Kimmel Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates Journal of Dental Research, November 1, 2007; 86(11): 1022 - 1033. [Abstract] [Full Text] [PDF]

				D Aguiar Bujanda, U Bohn Sarmiento, M. Cabrera Suarez, and J Aguiar Morales Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis Ann. Onc., March 1, 2007; 18(3): 556 - 560. [Abstract] [Full Text] [PDF]

				A. P. Grigg, P. Shuttleworth, J. Reynolds, A. P. Schwarer, J. Szer, K. Bradstock, C. Hui, R. Herrmann, and P. R. Ebeling Pamidronate Reduces Bone Loss after Allogeneic Stem Cell Transplantation J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3835 - 3843. [Abstract] [Full Text] [PDF]

				V. Guarneri, S. Donati, M. Nicolini, S. Giovannelli, R. D'Amico, and P. F. Conte Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years Oncologist, November 1, 2005; 10(10): 842 - 848. [Abstract] [Full Text] [PDF]

				F. Rainone Treating Adult Cancer Pain in Primary Care J Am Board Fam Med, November 1, 2004; 17(suppl_1): S48 - S56. [Abstract] [Full Text] [PDF]

				P. Conte and V. Guarneri Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens Oncologist, September 1, 2004; 9(suppl_4): 28 - 37. [Abstract] [Full Text] [PDF]

				B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer J. Clin. Oncol., November 1, 2003; 21(21): 4042 - 4057. [Abstract] [Full Text] [PDF]

				J R Ross, Y Saunders, P M Edmonds, S Patel, K E Broadley, and S R D Johnston Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer BMJ, August 30, 2003; 327(7413): 469. [Abstract] [Full Text] [PDF]